The present specification relates to a heterocyclic compound represented by Chemical Formula 1, and an organic light emitting device comprising the same.

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

Provided in the present disclosure is an organic compound, which relates to the technical field of organic materials. In the compound of the present disclosure, an electron-deficient nitrogen-containing heteroaryl and cyano are linked to adamantly, so that the LUMO energy level is deepened, thereby electron mobility is further improved. Further provided in the present disclosure are an electronic component and electronic apparatus comprising the described organic compound. The organic compound can improve the electron transport performance of electronic components. When used as an electron transport layer of an organic light-emitting electroluminescent device, the compound can improve the luminous efficiency and service life of the device and reduce the working voltage.

A micro-nano structure formed by self-assembling a compound represented by formula (I), an isomer thereof, a pharmaceutically acceptable salt, a hydrate or a solvate in an aqueous solution, a preparation method for the micro-nano structure, and use thereof are described. The micro-nano structure has the advantages of having high photothermal conversion efficiency, good photothermal stability, good photothermal effect and photodynamic effect, being easily degraded, and having high safety, and can be passively targeted to tumor sites, having a broad prospect in the diagnosis and treatment of cancers and skin diseases.

##STR00001##

A micro-nano structure formed by self-assembling a compound represented by formula (I), an isomer thereof, a pharmaceutically acceptable salt, a hydrate or a solvate in an aqueous solution, a preparation method for the micro-nano structure, and use thereof are described. The micro-nano structure has the advantages of having high photothermal conversion efficiency, good photothermal stability, good photothermal effect and photodynamic effect, being easily degraded, and having high safety, and can be passively targeted to tumor sites, having a broad prospect in the diagnosis and treatment of cancers and skin diseases.

##STR00001##